INSTATAB
DEAD

Add to watchlist:

No watchlists yet
View on USPTO

INSTATAB Trademark

Serial Number: 78931095

INSTATAB is a trademark filed by BIOVAIL LABORATORIES INTERNATIONAL SRL on July 17, 2006. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

BIOVAIL LABORATORIES INTERNATIONAL SRL (42 trademarks)

WELCHES
CHRIST CHURCH BB17154 , BB

Entity Type: 99

Trademark Details

Filing Date

July 17, 2006

Registration Date

Not Registered

Published for Opposition

January 1, 2008

Goods & Services

Pharmaceutical preparations and substances for the prevention, treatment and alleviation of stress; pharmaceutical preparations and substances for the prevention, treatment and alleviation of diabetes; pharmaceutical preparations and substances for controlling insulin levels; pharmaceutical preparations and substances for the prevention, treatment and alleviation of hypertension; pharmaceutical preparations and substances for the prevention, treatment and alleviation of angina; pharmaceutical preparations and substances for the cessation of smoking; pharmaceutical preparations and substances for the prevention and treatment of sexually transmitted diseases; pharmaceutical preparations and substances for the prevention and treatment of herpes; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the central nervous system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of depression; anti-depressants; pharmaceutical preparations and substances for the prevention, treatment and alleviation of sleep disorders; pharmaceutical preparations and substances for the prevention, treatment and alleviation of anxiety; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the cardio-vascular system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of acute myocardial infarctions; pharmaceutical preparations and substances for the prevention, treatment and alleviation of symptomatic congestive heart failure; pharmaceutical preparations and substances for the prevention, treatment and alleviation of asymptomatic left ventricular dysfunction; pharmaceutical preparations and substances, namely, fibrinolytic or thrombolytic agents; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the respiratory system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the endocrine system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the immune system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the musculo-skeletal system, namely, bone diseases and bone degenerative conditions; pharmaceutical preparations and substances for the prevention, treatment and alleviation of pain and inflammation, namely, pain relief medication and anti-inflammatories; pharmaceutical preparations and substances for the prevention, treatment and alleviation of migraines; pharmaceutical preparations and substances, namely, medicated skin care preparations for use in dermatology, namely, dermatitis and skin pigmentation diseases; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations and substances for use in ophthalmology; pharmaceutical preparations and substances for the treatment of polycystic ovary syndrome; pharmaceutical preparations and substances for the treatment of infertility; pharmaceutical preparations and substances for the prevention, treatment and alleviation of circulatory, neurologic, alimentary, auto-immune, pulmonary, musculoskeletal, lymphatic, gastrointestinal, bone sensory, viral, urinary, renal, infectious or metabolic diseases, illnesses, disorders or conditions; metformin; diltiazem; tramadol; carvedilol; bupropion; metoprolol; citalopram; zolpidem; fluoxetine; venlafaxine; lorazepam; and sumatriptan; rapidly dissolving drug delivery agents consisting of compounds that facilitate the delivery of a wide variety of pharmaceuticals

Filing History

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 22, 2014 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 22, 2014 REAP
ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Apr 25, 2011 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Apr 25, 2011 ABN6
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Apr 6, 2011 ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Mar 23, 2011 ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Oct 13, 2010 ASCK
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 2, 2010 EXRA
SOU EXTENSION 5 GRANTED
Oct 1, 2010 EX5G
SOU EXTENSION 5 FILED
Sep 21, 2010 EXT5
SOU TEAS EXTENSION RECEIVED
Sep 21, 2010 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 13, 2010 EXRA
SOU EXTENSION 4 GRANTED
Apr 12, 2010 EX4G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Apr 12, 2010 AITU
SOU EXTENSION 4 FILED
Mar 17, 2010 EXT4
SOU TEAS EXTENSION RECEIVED
Mar 17, 2010 EEXT
SOU EXTENSION 3 GRANTED
Sep 18, 2009 EX3G
SOU EXTENSION 3 FILED
Sep 15, 2009 EXT3
SOU TEAS EXTENSION RECEIVED
Sep 15, 2009 EEXT
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Jun 17, 2009 ASCK
SOU EXTENSION 2 GRANTED
Apr 8, 2009 EX2G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Apr 8, 2009 AITU
SOU EXTENSION 2 FILED
Mar 24, 2009 EXT2
SOU TEAS EXTENSION RECEIVED
Mar 24, 2009 EEXT
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jan 22, 2009 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jan 22, 2009 COAR
SOU EXTENSION 1 GRANTED
Sep 19, 2008 EX1G
SOU EXTENSION 1 FILED
Sep 19, 2008 EXT1
SOU TEAS EXTENSION RECEIVED
Sep 19, 2008 EEXT
NOA MAILED - SOU REQUIRED FROM APPLICANT
Mar 25, 2008 NOAM
POST PUBLICATION AMENDMENT - ENTERED
Feb 5, 2008 CHPB
ASSIGNED TO EXAMINER
Feb 5, 2008 DOCK
FAX RECEIVED
Jan 14, 2008 FAXX
PUBLISHED FOR OPPOSITION
Jan 1, 2008 PUBO
NOTICE OF PUBLICATION
Dec 12, 2007 NPUB
LAW OFFICE PUBLICATION REVIEW COMPLETED
Nov 23, 2007 PREV
ASSIGNED TO LIE
Nov 23, 2007 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 18, 2007 CNSA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sep 29, 2007 TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sep 27, 2007 TCCA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 27, 2007 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 27, 2007 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Sep 27, 2007 ERFR
FINAL REFUSAL E-MAILED
Mar 28, 2007 GNFR
FINAL REFUSAL WRITTEN
Mar 28, 2007 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 10, 2007 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 9, 2007 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 9, 2007 TROA
NON-FINAL ACTION E-MAILED
Dec 13, 2006 GNRT
NON-FINAL ACTION WRITTEN
Dec 13, 2006 CNRT
ASSIGNED TO EXAMINER
Dec 13, 2006 DOCK
NEW APPLICATION ENTERED
Jul 21, 2006 NWAP